MediWound, an Israeli developer of products to treat burns and wounds using non-surgical tissue repair, said on Wednesday it was starting a Phase III trial for its treatment for venous leg ulcers. The

MediWound has commenced a pivotal, multicentre Phase III VALUE trial to assess its bioactive debridement therapy, EscharEx, for treating venous leg ulcers (VLUs). The primary aim of the trial is to determine the therapy's safety and efficacy in achieving debridement and preparing the wound bed for VLUs healing.